12 research outputs found
Effect of α-Tomatine and Tomatidine on the Growth and Development of the Colorado Potato Beetle (Coleoptera: Chrysomelidae): Studies Using Synthetic Diets
Glycoalkaloids are found throughout the genera Solanum (potato) and Lycopersicon (tomato). Certain glycoalkaloids, i.e. , α-tomatine, solanocardenine, and leptine, have been implicated as resistance factors to the Colorado potato beetle, Leptinotarsa decemlineata Say. The allelochemical properties of these glycoalkaloids have primarily been demonstrated by studies in p/anta, correlating Colorado potato beetle resistance with high levels of foliar glycoalkaloids: solanocardenine in S. neocardenasii, α-tomatine in S. pinnatisectum, and leptine in S. chacoense. Although the evidence that these glycoalkaloids mediate resistance is compelling, controlled analyses of Colorado potato beetle response to purified glycoalkaloids, fed to insects in synthetic diets, are necessary to characterize the allelochemic nature of these compounds. In this study, Colorado potato beetle reared on a meridic, synthetic diet supplemented with increasing concentrations of α-tomatine exhibit retarded growth and delayed development. These effects were evident throughout the insects\u27 development, from egg to prepupal stage. Toma· tidine (the aglycone of α-tomatine) has no effect on Colorado potato beetle, suggesting that the tetrasaccharide moiety of the glycoalkaloid is essential for insecticidal activity, consistent with a membrane-lytic mechanism of action
Performance of Colorado potato beetle larvae, Leptinotarsa decemlineata (Say), reared on synthetic diets supplemented with Solanum glycoalkaloids
Performance of Colorado Potato Beetle Larvae, Leptinotarsa Decemlineata (Say), Reared on Synthetic Diets Supplemented with Solanum Glycoalkaloids
Illness Uncertainty, Perceived Control, and Psychological Distress Among Adolescents With Type 1 Diabetes
Adaptive fractional order fast terminal dynamic sliding mode controller design for antilock braking system (ABS)
“Let's Talk about Sex”: A Qualitative Study of Rwandan Adolescents' Views on Sex and HIV
Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US
Recommended from our members
Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial
BackgroundTenofovir disoproxil fumarate (TDF) decreases bone mineral density (BMD). We hypothesized that vitamin D3 (VITD3) would increase BMD in youth receiving TDF.MethodsThis was a randomized, double-blind, placebo-controlled trial of directly observed VITD3 vs placebo every 4 weeks for 48 weeks in youth aged 16-24 years with HIV, RNA load <200 copies/mL, taking TDF-containing combination antiretroviral therapy (TDF-cART) for ≥180 days. Participants (N = 214) received a daily multivitamin containing VITD3 400 IU and calcium 162 mg, plus monthly randomized VITD3 50000 IU (n = 109) or placebo (n = 105). Outcome was change from baseline to week 48 in lumbar spine BMD (LSBMD). Data presented are median (Q1, Q3).ResultsParticipants were aged 22.0 (21.0, 23.0) years, 84% were male, and 74% were black/African American. At baseline, 62% had 25-hydroxy vitamin D (25-OHD) <20 ng/mL. Multivitamin adherence was 49% (29%, 69%), and VITD3/placebo adherence 100% (100%, 100%). Vitamin D intake was 2020 (1914, 2168) and 284 (179, 394) IU/day, and serum 25-OHD concentration was 36.9 (30.5, 42.4) and 20.6 (14.4, 25.8) ng/mL at 48 weeks in VITD3 and placebo groups, respectively (P < .001). From baseline to week 48, LSBMD increased by 1.15% (-0.75% to 2.74%) in the VITD3 group (n = 99; P < .001) and 0.09% (-1.49% to 2.61%) in the placebo group (n = 89; P = .25), without between-group difference (P = .12). VITD3 group changes occurred with baseline 25-OHD <20 ng/mL (1.17% [-.82% to 2.90%]; P = .004) and ≥20 ng/mL (0.93% [-.26% to 2.15%]; P = .033).ConclusionsFor youth taking TDF-cART, LSBMD increased through 48 weeks with VITD3 plus multivitamin, but not with placebo plus multivitamin, independent of baseline vitamin D status.Clinical trials registrationNCT01751646